STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico
SSKNHORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) November 19-22, 2025, where it presented its XTRAC® excimer laser and TheraclearX® acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX® accounts in Mexico, reflecting growing adoption of this innovative acne treatment modality by dermatologists in the region.
STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering
SSKN(NASDAQ:SSKN) HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of $2.204.
STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
SSKNHORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides a corporate update.
STRATA Skin Sciences Expands Reimbursement Eligibility For Excimer Laser Treatments To Include Multiple Inflammatory And Auto-Immune Skin Conditions Beyond Original Psoriasis Indication
SSKNStrata Skin Sciences Q1 EPS $(0.58) Misses $(0.52) Estimate, Sales $6.81M Miss $7.28M Estimate
SSKNA Peek at Strata Skin Sciences's Future Earnings
SSKNStrata Skin Sciences FY 2024 GAAP EPS $(2.65) Misses $(1.39) Estimate, Sales $33.562M Beat $32.961M Estimate
SSKNEarnings Preview For Strata Skin Sciences
SSKNSTRATA Skin Sciences Announces Japanese Study Validating Technological Advantages Of Excimer Laser Over Excimer Light In Treating Vitiligo, Psoriasis, Alopecia Areata, And Atopic Dermatitis; Study Highlights Deeper Penetration And Greater Activation Of Me
SSKNMaxim Group Initiates Coverage On Strata Skin Sciences with Buy Rating, Announces Price Target of $6
SSKN